• Cosmo Pharmaceuticals reported Phase III 12-month results for clascoterone 5% topical solution in men with mild-to-moderate androgenetic alopecia, with results presented in this announcement.
• Data showed a safety and tolerability profile suitable for long-term use, with no meaningful systemic hormonal safety signal observed.
• Patients who stayed on treatment maintained continued hair growth over one year, while those switched to placebo lost part of earlier gains, supporting need for ongoing therapy.
• Cosmo started NDA and MAA preparations, with a US filing planned for early 2027.
• Full Phase III dataset slated for future publication in a peer-reviewed journal and presentation at major dermatology congresses.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmo Pharmaceuticals NV published the original content used to generate this news brief on April 15, 2026, and is solely responsible for the information contained therein.